


**REMARKS**

The specification has been amended to update the priority information. Claims 1-88 and 90-129 have been canceled, claim 89 has been amended, and new claims 130-153 have been added without prejudice or disclaimer of any previously claimed subject matter.

The unifying concept in the remaining claims is that each is a triazolopyridine, imidazolopyridine, or pyrazolopyrimidine nucleoside that has two non-hydrogen substituents in the 2'-position of the nucleoside, which represents the core of the invention.

Applicant respectfully submits that the claims of the above-referenced patent application are in condition for allowance and requests such action. If any issues remain that may be resolved by telephone, the Examiner is requested to call the undersigned at (404) 572-3451.

Respectfully submitted,

  
Sherry M. Knowles, Esq.  
Reg. No. 33,052

June 20, 2003  
King & Spalding, LLP  
45<sup>th</sup> Floor  
191 Peachtree Street, N.E.  
Atlanta, Georgia 30303  
404.572.4600  
K&S Docket: 06171.IDX1007 CON3